![]() ![]() Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively n = 510) or TC (75 and 600 mg/m2, respectively n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. ![]() In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS). Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |